stockrow
Friday 6 November 2026
Export TLX’s income statement to Excel — free account
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited’s revenue for fiscal 2025 (year ended December 2025) was $803.8 million, up 55.6% from fiscal 2024.
9.66
0.24
+2.55%
Follow TLX
Alert me
Telix Pharmaceuticals Limited (TLX) Current ratio
Telix Pharmaceuticals Limited's current ratio at the end of the quarter to 30 June 2026 was 2.0×, up 0.6× from fiscal 2025 (1.4×). That is below the Biotechnology industry median of 4.9× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 1.4× | (48.71%) |
| FY2024 | 2.8× | 97.35% |
| FY2023 | 1.4× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 2.0× | 41.23% |
| Dec 2025 | 1.4× | 6.97% |
| Jun 2025 | 1.3× | (52.05%) |
| Dec 2024 | 2.8× | 181.37% |
| 2 more quarters | Free account |
Current ratio against peers
| Company | Current ratio |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | 64.1× |
| VRDN Viridian Therapeutics, Inc. compare | 14.5× |
| DYN Dyne Therapeutics, Inc. compare | 12.0× |
| IDYA IDEAYA Biosciences, Inc. compare | 9.0× |
| CELC Celcuity, Inc. compare | 8.9× |
| VKTX Viking Therapeutics, Inc. compare | 7.3× |
| DNLI Denali Therapeutics Inc. compare | 6.2× |
| TLX Telix Pharmaceuticals Limited | 2.0× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 2.0× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)